Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
Express News | Vera Therapeutics Inc - to Announce Origin 3 Trial Results in Q2 2025
Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Express News | Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 Origin 3 Trial of Atacicept in Igan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $107
Cantor Fitzgerald analyst Pete Stavropoulos maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and sets the target price at $107.According to TipRanks data, the analyst has a success rate of 33
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $72
J.P. Morgan analyst Anupam Rama maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and adjusts the target price from $62 to $72.According to TipRanks data, the analyst has a success rate of 48.
Vera Therapeutics to Participate at September Investor Conferences
Vera Therapeutics Insiders Sell US$1.0m Of Stock, Possibly Signalling Caution
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $62
Vera Therapeutics Analyst Ratings
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $62
J.P. Morgan analyst Anupam Rama maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and adjusts the target price from $65 to $62.According to TipRanks data, the analyst has a success rate of 45.
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Intrinsic Value Is Potentially 88% Above Its Share Price
Express News | Vera Therapeutics Inc : JP Morgan Cuts Target Price to $62 From $65
Vera Therapeutics' Atacicept Secures Buy Rating Amid Strong Financials and Promising Clinical Trials
Vera Therapeutics | 10-Q: Q2 2024 Earnings Report
Wedbush Cuts Vera Therapeutics' Price Target to $30 From $32, Maintains Neutral Rating
Vera Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Vera Therapeutics 2Q Loss/Shr 62c >VERA